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Summary
Background Hot ﬂ ushes and night sweats (HFNS) aﬀ ect 65–85% of women after breast cancer treatment; they are 
distressing, causing sleep problems and decreased quality of life. Hormone replacement therapy is often either 
undesirable or contraindicated. Safe, eﬀ ective non-hormonal treatments are needed. We investigated whether 
cognitive behavioural therapy (CBT) can help breast cancer survivors to eﬀ ectively manage HFNS.
Methods In this randomised controlled trial, we recruited women from breast clinics in London, UK, who had 
problematic HFNS (minimum ten problematic episodes a week) after breast-cancer treatment. Participants were 
randomly allocated to receive either usual care or usual care plus group CBT (1:1). Randomisation was done in blocks 
of 12–20 participants, stratifying by age (younger than 50 years, 50 years or older), and was done with a computer-
generated sequence. The trial statistician and researchers collecting outcome measures were masked to group 
allocation. Group CBT comprised one 90 min session a week for 6 weeks, and included psycho-education, paced 
breathing, and cognitive and behavioural strategies to manage HFNS. Assessments were done at baseline, 9 weeks, 
and 26 weeks after randomisation. The primary outcome was the adjusted mean diﬀ erence in HFNS problem rating 
(1–10) between CBT and usual care groups at 9 weeks after randomisation. Analysis of the primary endpoint was done 
by modiﬁ ed intention to treat. The trial is registered, ISRCTN13771934, and was closed March 15, 2011.
Findings Between May 5, 2009, and Aug 27, 2010, 96 women were randomly allocated to group CBT (n=47) or usual 
care (n=49). Group CBT signiﬁ cantly reduced HFNS problem rating at 9 weeks after randomisation compared with 
usual care (mean diﬀ erence –1·67, 95% CI –2·43 to –0·91; p<0·0001) and improvements were maintained at 26 weeks 
(mean diﬀ erence –1·76, –2·54 to –0·99; p<0·0001). We recorded no CBT-related adverse events.
Interpretation Group CBT seems to be a safe and eﬀ ective treatment for women who have problematic HFNS after 
breast cancer treatment with additional beneﬁ ts to mood, sleep, and quality of life. The treatment could be incorporated 
into breast cancer survivorship programmes and delivered by trained breast cancer nurses.
Funding Cancer Research UK.
Introduction
Breast cancer is the most common cancer in women in 
the UK and, as a result of improved early detection and 
treatment, more women are now living longer with or 
surviving the disease.1 Hot ﬂ ushes and night sweats 
(HFNS) aﬀ ect 65–85% of women treated for breast 
cancer, often occurring while women are still adjusting 
to the eﬀ ects of cancer treatments. HFNS are more 
severe in this population than they are in healthy 
women and have a negative eﬀ ect on quality of life, 
mood, and sleep.2–4 Chemotherapy or adjuvant endocrine 
treatments can compromise or lead to failure of ovarian 
function, resulting in rapid reduction of oestrogen 
concentrations, which induces or exacerbates HFNS. 
HFNS can in turn reduce adherence to endocrine 
therapy if left untreated.5–7
Hormone replacement therapy is an eﬀ ective 
treatment for HFNS, but is generally contraindicated 
for patients with breast cancer because it can increase 
the risk of breast cancer recurrence, and HFNS can re-
turn in women who discontinue hormone replacement 
therapy.8 A Cochrane review of non-hormonal medical 
treatments concluded that clonidine (an antihypertensive 
drug), gabapentin (an anticonvulsant that works through 
an unknown mechanism), selective serotonin reuptake 
inhibitors (SSRIs), and serotonin-norepinephrine 
reuptake inhibitors (SNRIs) showed a mild to moderate 
eﬀ ect on the frequency of HFNS in women with a 
history of breast cancer (reductions of between 15% and 
58%; average 37%).9 Three trials done since the review 
was undertaken recorded similar reductions.10–12 Various 
side-eﬀ ects of medical treatments were reported—eg, 
dry mouth, sleep problems, and nausea—and short 
follow-up limited conclusions about long-term 
outcomes.9 Some SSRIs (paroxetine and ﬂ uoxetine), but 
not all, might reduce the eﬀ ectiveness of endocrine 
treatments.13 Evidence of improvements to quality of life 
is mixed; six of 12 studies of non-hormonal drugs 
reported no eﬀ ect.10–12,14 Moreover, many breast cancer 
survivors prefer to use non-medical treat ments.3 
For non-pharmacological therapies—eg, vitamins, 
magnetic devices, or acupuncture—the Cochrane review 
Articles
310 www.thelancet.com/oncology   Vol 13   March 2012
concluded that outcomes were either inconsistent or 
not statistically signiﬁ cant.9 Consequently, a need exists 
for safe, acceptable, and eﬀ ective non-hormonal treat-
ments that are free from side-eﬀ ects to help these 
women to manage HFNS.15,16
An intervention based on cognitive behavioural therapy 
(CBT) has been developed,17 including psychoeducation, 
paced breathing and relaxation, and CBT to help women 
to manage HFNS. This intervention has been shown to 
be acceptable to women and has shown promise in 
exploratory trials of one-to-one and group CBT.17,18 The 
treatment is based on a model of the hypothesised causal 
mechanisms and maintaining factors of HFNS, which 
include anxiety, stress, embarrassment, negative beliefs, 
catastrophic thoughts, and avoidance behaviours.19,20 In a 
pilot, uncontrolled trial of group CBT, 17 women who had 
been treated for breast cancer reported an average 
49% reduction in HFNS problem rating and a 38% 
reduction in self-reported HFNS frequency.18
HFNS frequency has generally been considered to be 
the target of treatments, but studies have suggested that 
problem rating (ie, the extent to which HFNS are 
bothersome and interfere with life) should be the 
primary outcome in clinical trials because it is associated 
with help-seeking behaviour and quality of life to a 
greater extent than is frequency of HFNS.21,22 Sternal skin 
conductance (SSC) monitoring is the most valid 
physiological measure of HFNS, but is rarely included 
in trials. Subjective and physiological measures assess 
diﬀ erent aspects of HFNS.23 MENOS 1 is a randomised 
controlled trial of group CBT compared with usual care 
with a 26-week follow-up. We hypothesised that 
participants would report less problematic HFNS and 
fewer HFNS, improved mood, sleep, and health-related 
quality of life after group CBT compared with individuals 
who received usual care. We measured subjective 
frequency and problem rating of HFNS and SSC 
monitoring of HFNS frequency, to establish whether the 
treatment aﬀ ects physiological or psychological factors, 
or both.
Methods
Study design and participants
The study design is described in detail in the trial 
protocol.20 Brieﬂ y, recruitment took place between 
March 17, 2009, and Aug 27, 2010. Women attending 
breast or oncology clinics in southeast London, UK, 
were oﬀ ered the trial by clinicians and research nurses. 
They could also apply for inclusion by responding to 
leaﬂ ets and posters displayed in clinics.
English-speaking women older than 18 years were 
eligible if they had had at least ten problematic HFNS 
per week (conﬁ rmed by a 2-week diary and a screening 
interview) for a duration of 2 months or more, had 
completed medical treatment for breast cancer (surgery, 
radiotherapy, or chemotherapy), and had no evidence of 
other cancers or metastases. Women taking adjuvant 
endocrine treatment were eligible. Because many 
women use treatments for HFNS but still have 
troublesome symptoms and seek further treatment, they 
were not excluded if they had been using the treatment 
consistently for 2 months or more, and planned to 
continue at the same dose during the trial. Those unable 
to attend sessions or who were seeking treatment for 
mood disorders rather than for HFNS were not eligible. 
All participants gave written, informed consent before 
taking part. Ethical approval was obtained from the UK 
NHS Research Ethics Committee.
Randomisation and masking
Randomisation was done in cohort groups. After base line 
assessment and receipt of consent from 12–20 par ticipants, 
the trial clinical psychologist (MJS) sent participants’ 
identiﬁ cation details to a programmer at the Clinical Trials 
Unit at King’s College London, UK, for randomisation. 
The number of women in each cohort was determined on 
the basis of an estimation of an optimum of six to ten 
participants in group CBT. The programmer created a 
computer-generated random isation sequence, allocating 
participants in a one-to-one ratio, stratiﬁ ed by age 
(<50 years, ≥50 years), with randomly varying block size. 
This process was repeated for each cohort group so that 
allocation did not aﬀ ect the allocation sequence of 
subsequent cohorts. The clinical psychologist, who did the 
group CBT treatment, was sent the allocation results and 
then informed participants of their treatment allocation. 
Although neither participants nor the clinical psycho logist 
could be masked to group allocation, researchers collecting 
outcome data and analysing results were masked. 
Speciﬁ cally, at 9-week and 26-week assessments, women 
were met by a separate researcher who collected 
questionnaires and who also asked the women not to 
disclose their treatment allocation to the researcher who 
did the outcome assessments. To check whether the trial 
coordinator (EM) was successfully masked, after 9-week 
assessments for each cohort she noted which group she 
thought participants had been allocated to. Masking was 
successful, with the allocation of 51% of participants 
correctly identiﬁ ed. The trial statistician was masked to 
group identity until analyses were complete.
Procedures
Assessments took place at baseline, 9 weeks after 
randomisation (typically 2 weeks after treatment), and 
26 weeks after randomisation. About 2 weeks before 
participants attended a baseline assessment, a researcher 
explained the study, assessed eligibility by telephone, and 
posted written information and a 2-week diary to be 
updated on a daily basis to record HFNS frequency. At 
baseline assessment, eligibility was conﬁ rmed; partici-
pants were able to ask questions before signing a standard 
consent form. Women were asked about their breast 
cancer treatment history, menopause symptoms, and 
medical history. They completed a questionnaire covering 
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demographic characteristics and baseline measures and 
were given a small SSC monitor and a magnetic event 
marker bracelet worn for 24 h. They were asked to 
indicate when they had an HFNS by passing the magnet 
over the monitor; they were encouraged to do usual 
activities and were shown how to remove the monitor to 
shower or bathe.
Participants allocated to receive group CBT attended a 
90 min session every week for 6 weeks, between 
June, 2009, and October, 2010 (panel 1). A treatment 
manual was produced in advance of the study, which 
contained detailed session content, presentation slides 
and handouts, and notes for facilitators. A clinical 
psychologist was trained to deliver the sessions with the 
help of an assistant (ﬁ ve assistants took part over the 
course of the study). All sessions were audio taped, then 
10% were randomly selected (with a computer-generated 
random number sequence) and a psychologist (MSH) 
experienced in cognitive behavioural therapy for HFNS, 
rated them for adherence to the treatment manual, by 
indicating on coding sheets the extent to which the 
group leader covered each topic. Coding sheets included 
speciﬁ c components of the intervention (eg, reviewing 
home work, providing information about the role of 
stress, demonstrating paced breathing in the session, 
group discussion of behaviours relating to HFNS) 
developed for the trial (appendix).
All participants received usual care—they had access to 
clinical specialists and cancer support services, either 
through routine follow-up appointments or as part of a 
breast cancer survivorship programme in southeast 
London (panel 1). At the second assessment (9 weeks 
after randomisation) they repeated the baseline question-
naires and 24-h SSC HFNS monitoring, and documented 
any health and lifestyle changes as well as use of services 
and treatments in the previous 9 weeks (the latter was 
used to index usual care in both treatment groups). 
At 26 weeks after randomisation, questionnaires were 
sent containing the same measures; face to face or 
telephone interviews were done by an independent 
psychologist after ﬁ nal measures were completed to 
obtain women’s responses to being in the trial and their 
views about the treatment (for those in the CBT group). 
HFNS treatments used during the trial were recorded for 
each participant at each timepoint. Follow-up was 
completed by March 15, 2011.
Outcomes
The primary outcome was the HFNS problem rating 
(hot ﬂ ush rating scale24) at 9 weeks after randomisation. 
Problem rating—ie, the extent to which symptoms are 
bothersome and interfere with life—was chosen, before 
the trial began,20 as the primary outcome measure 
because problem rating, rather than frequency, is 
associated with help-seeking and quality of life, and it 
has been recommended as the most appropriate patient-
reported outcome measure in clinical trials of HFNS 
treatments.21,22 Problem rating and severity tend to 
be associated with each other—neither are strongly 
associated with frequency of HFNS.21
Secondary outcomes included HFNS problem rating 
at 26 weeks, and HFNS frequency, mood, and health-
related quality-of-life measures at 9 weeks and 26 weeks 
after randomisation. Problem rating of HFNS (hot ﬂ ush 
rating scale24) was calculated as the mean of three 
10-point items that assess the extent to which symptoms 
Panel 1: Intervention content
Group cognitive behavioural therapy (CBT)
The group CBT was psycho-educational, structured, and interactive with presentations, 
group discussion, handouts, and weekly homework. Paced breathing and relaxation were 
practised at each session and participants were given a relaxation and paced breathing 
audio CD to practise at home daily and during hot ﬂ ushes and night sweats (HFNS). 
Women recorded their HFNS in weekly diaries.
Session one introduced the cognitive behavioural model including physiological, cognitive, 
behavioural, and emotional components of HFNS; provided information about the 
physiology of HFNS; and introduced paced breathing. Participants described their 
experiences of HFNS in the context of breast cancer, outlined their goals for treatment, 
discussed and recorded particular triggers of hot ﬂ ushes, and practised relaxation.
Session two focused on the role of stress in potentiating HFNS and CBT strategies for the 
reduction of stress and anxiety. Paced breathing was introduced and practised as homework.
Session three focused on cognitive (eg, catastrophic thinking and overly negative beliefs 
about hot ﬂ ushes) and behavioural reactions (eg, avoidance of activities) to hot ﬂ ushes. 
Participants planned ways to manage ﬂ ushes in social situations and paced breathing to 
manage ﬂ ushes was introduced. They practised paced breathing at onset of a ﬂ ush and 
implemented cognitive behavioural strategies to manage hot ﬂ ushes as homework. They 
also completed sleep diaries in preparation for the sleep sessions.
Session four focused on understanding night sweats and improving sleep habits and the 
application of behavioural strategies to reduce wakefulness after night sweats. 
Participants identiﬁ ed ways in which they could change sleep habits, which they 
implemented as homework.
Session ﬁ ve focused on the cognitive component of sleep problems, including sleep-related 
anxieties or general worries leading to further wakefulness. CBT strategies were developed 
for the management of night sweats.
Session six was a review session and participants made action plans to maintain cognitive 
and behavioural changes, including dealing with setbacks.
Usual care
All women had completed active breast cancer treatment and were typically followed up 
every 6 months by an oncologist or clinical nurse specialist, with additional appointments 
as needed. Additionally, those treated in UK National Health Service hospitals in 
southeast London were oﬀ ered telephone support as part of the cancer survivorship 
programme. Women were sent an information leaﬂ et produced by Breast Cancer Care and 
oﬀ ered telephoned support every 2 weeks (average seven telephone calls, maximum ten). 
Nurses gave information about HFNS, advised on treatment options and practical ways of 
symptom management, and oﬀ ered instructions for paced breathing and relaxation. 
77 (80%) participants had access to the survivorship programme. The remainder were no 
longer attending follow-up appointments at the hospital (n=7), or were not treated at 
hospitals in the southeast London cancer network (n=12). Therefore, individuals in the 
usual care group received information and had access to high quality support services.
See Online for appendix
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are problematic and interfere with daily life; 10 indicates 
most problematic HFNS. A diﬀ erence of two points or 
more is regarded as clinically relevant.17,18,25 The scale has 
good internal consistency (Cronbach α=0·9) and test-
retest reliability (r=0·8). HFNS frequency was measured 
with the HFNS frequency subscale (total number of 
HFNS reported in the past week) of the Hot Flush Rating 
Scale.24 This subjective HFNS frequency measure 
correlated with daily diary recordings of HFNS in a 
previous study (r=0·9, p<0·0001).24
SSC monitoring and participant-reported ﬂ ushes were 
assessed over a 24-h monitoring period (with the Bahr 
SSC monitor [Simplex Scientiﬁ c; Middleton, WI, USA]). 
A 6-cm by 6-cm monitor measured SSC every 10 s by 
passing an electric current across two electrodes attached 
to the sternal region of the chest. Women also indicated 
occurrence of a hot ﬂ ush by passing a magnetic event 
marker over the monitor, which recorded the time. HFNS 
were deﬁ ned by increases of 2 μS or more occurring 
within 30 s, and not within 15 min duration since the 
previous HFNS. This is the standard criteria used for 
SSC monitoring validated with ambulatory and laboratory 
equipment.23 The sum of physiological and participant-
reported (event-marked) HFNS were extracted for 
analysis. When less than 24 h of data were available, 
number of HFNS was adjusted so that it was equivalent 
to the rate of HFNS per 24 h.
The General Health Survey Short Form 36 (SF-36)26 
was used to measure dimensions of health-related 
quality of life (general health, mental health, physical 
role limitation, emotional role limitation, physical 
Figure 1: Trial proﬁ le
CBT=cognitive behavioural therapy. HFRS=hot ﬂ ush rating scale.
43 completed HFRS at week 9 45 completed HFRS at week 9
96 randomly allocated to treatment
1 unable to attend
1 ill health
1 symptoms ceased
1 chose not to participate
1 chose not to participate
1 died
2 could not be contacted
    at week 9
47 cognitive behavioural therapy
      6 in cohort one
      9 in cohort two
      7 in cohort three
      7 in cohort four
      6 in cohort ﬁve
      6 in cohort six
      6 in cohort seven
49 usual care
        5 in cohort one
      10 in cohort two
        7 in cohort three
        7 in cohort four
        6 in cohort ﬁve
        7 in cohort six
        7 in cohort seven
3 could not be contacted 2 could not be contacted
1 family problems
2 ill health
40 completed HFRS at week 26 40 completed HFRS at week 26
43 analysed 45 analysed
278 screened for eligibility
177 excluded
        79 not meeting inclusion criteria
              18 symptoms not problematic
                 5 cancers had metastasised
                 8 unable to attend CBT sessions
              20 lived too far away
              19 never had breast cancer
                 1 died
                 8 undergoing cancer treatment
 98 chose not to participate
101 consented to take part and 
        completed baseline assessment






Age at randomisation (years; mean 
[SD])
53·16 (8·10) 54·05 (7·76)
Individuals younger than 50 years 15 (32%) 17 (35%)
Ethnic origin
White 42 (89%) 40 (82%)
Black 4 (9%) 5 (10%)
Other 1 (2%) 4 (8%)
Number of women who have had 
children
29 (62%) 31 (63%)
Married or living with partner 29 (62%) 28 (57%)
Educated beyond 16 years of age 30 (64%) 33 (67%)
Employed 30 (64%) 32 (65%)
Mean body-mass index (kg/m²; SD) 27·13 (5·30) 27·51 (6·90)
Premenopausal before diagnosis 24 (51%) 24 (49%)
Perimenopausal before diagnosis 9 (19%) 8 (16%)
Postmenopausal before diagnosis 12 (25%) 16 (33%)
Time since breast cancer diagnosis 
(months; mean [SD])
47·75 (53·38) 31·08 (30·63)
Treatment history
Surgery 46 (98%) 49 (100%)
Chemotherapy 26 (55%) 37 (76%)
Radiotherapy 36 (77%) 41 (84%)
Taking endocrine treatment at 
baseline
34 (72%) 36 (73%)
Chronicity of HFNS (months; 
mean [SD])
23·53 (34·46) 28·48 (43·11)
Taking a prescribed drug for HFNS at 
baseline
7 (15%) 6 (12%)
Baseline HFNS problem-rating 
(mean [SD])
6·52 (2·43) 6·12 (2·02)
Baseline HFNS frequency (number 
per week; mean [SD]) 
72·84 (37·89) 66·34 (40·18)
Data are n (%), unless otherwise stated. HFNS=hot ﬂ ushes and night sweats.
Table 1: Demographic and clinical baseline characteristics
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functioning, social functioning, vitality, and bodily 
pain); scores range from 0 to 100 (a higher score 
indicates better health).
The Women’s Health Questionnaire (WHQ),27 a 
measure of physical and emotional symptoms designed 
for and standardised on women aged 45–65 years, is 
widely used in studies of menopausal women and has 
high internal reliability. The WHQ is comprised of 
37 items that assess, for example, an individual’s 
depressed mood, anxiety or fears, and problems sleeping. 
Participants rate each item on a 4-point scale, according to 
the extent to which they are experi encing each item, and 
subscale scores are calculated, ranging from 0–1 (higher 
scores indicate poorer wellbeing). The depressed mood 
subscale has concurrent validity with the GHQ and the 
WHQ has good internal reliability for subscales (Cronbach 
α 0·70–0·84) and test-retest reliability (0·78–0·96). Five 
subscales were included: depressed mood, anxiety or 
fears, sleep problems, memory or concentration, and 
somatic symptoms. We also included measures of process 
variables including beliefs, behaviours, and stress, which 
are described elsewhere.20
Adherence to group CBT was measured by the number 
of sessions attended and the number of times that a 
participant practised relaxation or paced breathing each 
week. Number and type of adverse events were examined 
in both groups to assess treatment safety in accordance 
with the protocol. The trial data management committee 
reviewed adverse events and assessed whether they were 
related to the intervention. Recurrence of breast cancer, 
skin irritation due to the hot ﬂ ush monitor, and clinically 
signiﬁ cant deterioration in mood were identiﬁ ed as 
possible expected unrelated adverse events, and clinically 
signiﬁ cant deterioration in mood as a result of group 
CBT was identiﬁ ed as a potential treatment-related 
adverse event. The trial clinical psychologist recorded 
incidents of mood deterioration and referred patients for 
treatment, as appropriate. Recurrence of breast cancer or 
secondary cancers were classiﬁ ed as expected but 
unrelated serious adverse events.28
Statistical analysis
We calculated that a sample size of 96 women was needed 
to provide 90% power to detect a two-point diﬀ erence 
(SD 2·4; standardised eﬀ ect size 0·8) in mean HFNS 
problem rating for the comparison of CBT to usual care 
at 9 weeks after randomisation. This sample size allowed 
for 20% loss to follow-up, a variance inﬂ ation factor of 
1·49 (intraclass correlation 0·07,29 eight participants per 
group) to power for expected clustering of outcomes, and 
an HFNS problem rating baseline-to-outcome correlation 
of 0·4 on analysis of covariance with two-sided 5% 
signiﬁ cance levels.
The statistical analysis plan was ﬁ nalised and approved 
by the trial team before completion of data collection. 
p values of less than 0·05 were regarded as signiﬁ cant for 
all analyses. Analyses were based on modiﬁ ed intention-to-
treat sample (excluding those who contributed no data). 
We assessed the primary outcome with a linear mixed 
model; covariates were treatment group, baseline HFNS 
problem rating score, the stratiﬁ cation factor age (as a 
dichotomous category, split at 50 years), and time. A time-
by-treatment interaction term was included to allow 
estimates at the individual timepoints to be summarised. 
The model for problem rating incorporated two levels of 
random intercepts by participant and cohort group. The 
modelling was done with the assumption that data were 
missing at random and predictors of missing data 
(treatment group) were included in the modelling. We used 
a logistic model to assess predictors of missing data, and to 
examine all baseline clinical and demographic variables. 
Categorical outcomes, including adverse events were 
compared with Fisher’s exact test. We also analysed 
secondary outcomes with mixed linear regression models 
with random participant and cohort group intercepts and a 
time-by-treatment interaction term; covariates in the model 
were treatment group, baseline value of outcome, the strati-
ﬁ cation factor age, and time. Proportions and associated 
CIs were estimated from Wilson’s binomial distribution. 





CBT vs usual care* (adjusted mean 
diﬀ erence [SE, 95% CI; p value])
Baseline 6·52 (2·43) 6·12 (2·02) ··
9 weeks 3·53 (1·98) 4·95 (2·24) –1·67 (0·39, –2·43 to –0·91; <0·0001)
26 weeks 3·13 (1·94) 4·60 (2·48) –1·76 (0·40, –2·54 to –0·99; <0·0001)
*Adjusted analysis used cohort number as a random eﬀ ect and a covariate for the binary age stratiﬁ cation factor.
Table 2: Hot ﬂ ush and night sweats problem-rating scores
Figure 2: Changes in problem-rating scores for hot ﬂ ushes and night sweats
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26 weeks with two-sided 95% CIs. We used Stata (version 
11.0) for all statistical analyses. The trial is registered with 
Current Controlled Trials, number ISRCTN13771934.
Role of the funding source
The sponsor of the study had no role in the study design, 
data collection, data analysis, data interpretation, or 
writing of the report. The corresponding author had full 
access to all the data in the study and had ﬁ nal 
responsibility for the decision to submit for publication. 
Results
We randomly allocated 96 women to treatment between 
May 5, 2009, and Aug 27, 2010, most of whom remained 
in the trial (ﬁ gure 1). Withdrawal rates were much the 
same in both treatment groups (p=0·99 at 9 weeks; 
p=0·79 at 26 weeks), as were baseline demographic and 
clinical characteristics of participants (table 1). On 
starting the trial, HFNS were frequent and problematic 
with a mean of 69 per woman (SD 39) occurring per week 
for an average of 2 years, with a mean problem rating of 
6·3 out of 10 (table 1). 20 women were taking herbal 
remedies or complementary therapies for HFNS at 
baseline, all of whom were symptomatic. 13 women were 
taking non-hormonal prescribed drugs (table 1): hormone 
replacement therapy (one woman in each group), SSRI 
(two women in the CBT group and three in the usual care 
group), gabapentin (one woman in each group), clonidine 
(two women in the CBT group), gabapentin plus SSRI 
(one woman in the CBT group), and clonidine plus SSRI 
(one woman in the usual care group).
Problem rating scores at 9 weeks and 26 weeks were 
lower in the CBT group than they were in the usual care 
group (table 2). There was a signiﬁ cant diﬀ erence 
between groups in the primary outcome—HFNS 
problem rating at 9 weeks following randomisation 
(adjusted mean diﬀ erence of –1·67, 95% CI –2·43 to –0·91; 
p<0·0001) with a greater reduction from baseline in 
problem rating in the CBT group compared to the usual 
care group. At 9 weeks, the change in problem rating 
from baseline was –3·05 (SD 2·3) in the CBT group, 
compared with –1·06 (SD 1·7) in usual care group, 
equating to a 46% reduction in the CBT group and a 
19% reduction in the usual care group. At 26 weeks, the 
problem rating had decreased from baseline by 
52% (mean change –3·39, SD 2·3) in the CBT group and 
by 25% (mean change –1·26, SD 2·2) in the usual care 
group (table 2; ﬁ gure 2).
We recorded no signiﬁ cant diﬀ erence between groups in 
HFNS frequency, or in the hot ﬂ ush frequency and night 
sweat frequency subscales when analysed separately, at 
9 weeks or 26 weeks (table 3 and appendix). Compared 
with baseline, both groups reported non-signiﬁ cantly 
fewer HFNS at 9 weeks (21% in the CBT group and 24% 
in the usual care group) and 26 weeks (38% in both 
groups). We recorded little change in 24-h rate of HFNS at 
9 weeks, measured either by sternal skin conductance or 
participant-reported event markers; all frequency meas-
ures showed large variability in response (table 3).
Women in the CBT group reported less depressed 









Baseline 72·84 (37·89) 66·34 (40·18) ·· ··
9 weeks 57·72 (43·73) 50·31 (32·44) 2·89 (7·03) –10·89 to 16·67
26 weeks 45·33 (45·93) 41·37 (28·90) –5·21 (7·39) –19·69 to 6·27
Hot ﬂ ush frequency
Baseline 58·64 (32·16) 52·98 (37·93) ·· ··
9 weeks 45·60 (38·00) 36·76 (29·18) 6·63 (6·51) –6·13 to 19·40
26 weeks 37·46 (41·41) 30·77 (25·40) 0·95 (6·76) –12·29 to 14·20
Night sweats frequency
Baseline 16·31 (14·84) 13·50 (10·13) ·· ··
9 weeks 12·12 (9·93) 13·30 (8·69) –2·09 (1·93) –5·86 to 1·69
26 weeks 8·48 (9·13) 10·67 (9·97) –3·31 (2·03) –7·28 to 0·66
24 h sternal skin conductance frequency (n=89)
Baseline 9·38 (8·83) 11·09 (9·31) ·· ··
9 weeks 12·05 (8·03) 10·23 (6·80) 2·29 (1·48) –0·62 to 5·19
26 weeks ·· ·· ·· ··
24 h event-marker frequency (n=89)
Baseline 10·83 (8·96) 9·11 (8·33) ·· ··
9 weeks 10·00 (7·84) 7·76 (5·10) 1·91 (1·51) –1·04 to 4·87
26 weeks ·· ·· ·· ··
WHQ depressed mood
Baseline 0·23 (0·26) 0·31 (0·27) ·· ··
9 weeks 0·13 (0·16) 0·28 (0·24) –0·14 (0·05)* –0·23 to –0·06
26 weeks 0·13 (0·19) 0·28 (0·26) –0·13 (0·05)* –0·22 to –0·05
WHQ somatic symptoms
Baseline 0·56 (0·26) 0·55 (0·25) ·· ··
9 weeks 0·44 (0·24) 0·46 (0·24) –0·08 (0·06) –0·21 to 0·04
26 weeks 0·45 (0·23) 0·53 (0·23) –0·03 (0·06) –0·16 to 0·09
WHQ anxiety or fears
Baseline 0·34 (0·25) 0·45 (0·30) ·· ··
9 weeks 0·23 (0·27) 0·40 (0·33) –0·12 (0·06)† –0·24 to –0·01
26 weeks 0·24 (0·31) 0·39 (0·31) –0·10 (0·06) –0·21 to 0·01
WHQ sleep problems
Baseline 0·63 (0·30) 0·72 (0·29) ·· ··
9 weeks 0·37 (0·31) 0·65 (0·32) –0·26 (0·07)‡ –0·39 to –0·12
26 weeks 0·43 (0·37) 0·61 (0·34) –0·16 (0·07)† –0·29 to –0·02
WHQ memory and concentration
Baseline 0·75 (0·34) 0·72 (0·36) ·· ··
9 weeks 0·59 (0·36) 0·70 (0·32) –0·14 (0·06)† –0·27 to –0·02
26 weeks 0·51 (0·37) 0·62 (0·36) –0·14 (0·06)† –0·26 to –0·02
SF-36 physical functioning
Baseline 66·17 (22·89) 74·89 (22·27) ·· ··
9 weeks 75·38 (24·24) 79·23 (21·96) 4·76 (3·47) –2·03 to 11·56
26 weeks 74·13 (24·96) 73·88 (27·37) 8·86 (3·46)† 2·09 to 15·64
SF-36 role—physical
Baseline 53·72 (43·29) 49·46 (40·31) ·· ··
9 weeks 60·00 (40·35) 60·90 (39·65) –1·09 (8·14) –17·03 to 14·85
26 weeks 55·77 (43·10) 51·92 (44·20) 2·63 (8·17) –13·39 to 18·65
(Continues on next page)
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week 26 compared with those in the usual care group 
(table 3 and appendix). Women receiving CBT also 
reported less anxiety than did women in the usual 
care group at 9 weeks, but this diﬀ erence was not 
statistically signiﬁ cant at 26 weeks (table 3). We recorded 
small improvements in memory and concentration of 
participants in the CBT group compared with those in 
the usual care group, but no statistically signiﬁ cant 
diﬀ erences in somatic symptoms (table 3). At 26 weeks, 
women in the CBT group reported signiﬁ cantly better 
social functioning, physical functioning, and improved 
general health (at both 9 weeks and 26 weeks) than did 
women in the usual care group, according to the 
SF-36 assessments (table 3). Compared with women in 
the usual care group, women in the CBT group reported 
better mental health at 9 weeks and less bodily pain at 
26 weeks (table 3). We recorded no signiﬁ cant diﬀ erences 
between the groups in emotional role functioning or 
vitality subscales (table 3).
Although we did not record a mean two-point dif-
ference between treatment groups (ﬁ gure 3), a greater 
percentage of individuals had reached this two-point 
threshold in the CBT group than in the usual care group 
at both 9 weeks (65% [95% CI 50–78] vs 38% [25–52]) 
and 26 weeks (78% [62–88] vs 33% [20–48]). This 
exploratory analysis suggests that improvement from 
baseline was clinically better in the CBT group than it 
was in the usual care group (ﬁ gure 3).
In the 10% of sessions assessed for quality assurance, 
CBT was delivered according to the treatment manual, 
with 98–100% adherence. Training and clinical supervision 
were provided by a consultant clinical psychologist (MSH) 
throughout the study. Participant adherence to treatment 
was good; 39 (91%) of 43 participants who received CBT 
attended at least four of six sessions, and relaxation or 
paced breathing was practised, on average, 29 times each 
week (SD 26·93).
Individuals taking prescribed drugs for HFNS tended 
to continue them throughout the trial. Exceptions were 
one participant who stopped taking ﬂ uoxetine (CBT 
group), and one woman who stopped taking clonidine 
(usual care group). Three women started homoeopathy 
or herbal remedies (one in the CBT group, two in the 
usual care group), and one woman in the usual care 
group started acupuncture. When the adjusted primary 
analyses were repeated excluding these ﬁ ve participants, 
the estimates and CIs remained within the same margins 
(week 9 hot ﬂ ush problem rating, CBT vs usual care mean 
diﬀ erence –1·58, 95% CI –2·38 to –0·79; p<0·0001; week 
26 hot ﬂ ush problem rating, CBT vs usual care mean 
diﬀ erence –1·77, –2·59 to –0·95; p<0·0001).
We recorded six adverse events, three in the CBT group 
and three in the usual care group. One participant died 
of an unrelated disorder before the treatment phase 
(usual care group), we recorded two reoccurrences of 
breast cancer (one in each group), and one woman 
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SF-36 bodily pain
Baseline 46·15 (22·73) 52·99 (21·64) ·· ··
9 weeks 53·68 (23·98) 52·16 (22·57) 6·35 (4·20) –1·89 to 14·59
26 weeks 51·00 (22·50) 46·58 (22·18) 9·85 (4·20)† 1·61 to 18·09
SF-36 general health
Baseline 48·10 (15·94) 49·32 (16·77) ·· ··
9 weeks 51·84 (14·58) 47·68 (17·81) 5·36 (2·53)† 0·40 to 10·32
26 weeks 50·34 (15·42) 44·98 (19·83) 7·11 (2·53)* 2·15 to 12·07
SF-36 vitality
Baseline 35·33 (16·10) 38·13 (16·50) ·· ··
9 weeks 39·63 (15·23) 38·89 (17·79) 3·57 (2·92) –2·16 to 9·29
26 weeks 40·31 (17·48) 38·96 (15·72) 3·46 (2·92) –2·26 to 9·17
SF-36 social functioning
Baseline 67·02 (31·43) 71·20 (28·00) ·· ··
9 weeks 75·30 (25·39) 75·64 (25·96) 3·01 (4·97) –6·72 to 12·74
26 weeks 77·50 (27·18) 62·81 (29·48) 16·29 (4·96)* 6·57 to 26·00
SF-36 role—emotional
Baseline 67·39 (42·45) 55·56 (42·64) ·· ··
9 weeks 75·61 (38·02) 64·10 (40·02) 7·48 (7·97) –8·14 to 23·10
26 weeks 73·50 (37·60) 60·68 (42·49) 7·66 (8·07) –8·14 to 23·47
SF-36 mental health
Baseline 67·57 (17·89) 62·52 (17·37) ·· ··
9 weeks 74·63 (14·22) 66·46 (14·20) 6·03 (2·95)† 0·24 to 11·81
26 weeks 70·70 (19·24) 64·5 (16·06) 3·86 (2·96) –1·94 to 9·65
For the Women’s Health Questionnaire (WHQ),27 norms for women aged 45–65 years (n=682) are as follows (mean 
[SD]): depressed mood, 0·22 (0·23); somatic symptoms, 0·39 (0·25); anxiety or fears, 0·35 (0·28); sleep problems, 0·45 
(0·36); and memory and concentration, 0·47 (0·36). HFNS=hot ﬂ ushes and night sweats. SF-36=General Health Survey 
Short Form 36.26 *p<0·01. †p<0·05. ‡p<0·0001. 
Table 3: Eﬀ ect of treatment on hot ﬂ ushes and night sweats
Figure 3: Proportion of patients with a reduction of two or more points in 
the hot ﬂ ush problem-rating scale from baseline
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Two women (both in the usual care group) had mild 
reactions to the hot ﬂ ush monitor (a reaction to the 
adhesive used on the electrode patch). None of the 
adverse events were related to CBT.
Discussion
Our ﬁ ndings suggest that CBT is safe, acceptable, and 
eﬀ ective in helping women to manage hot ﬂ ushes and 
night sweats after breast cancer treatment, with additional 
beneﬁ ts to mood, sleep, and some aspects of quality of 
life. After group CBT, women reported less problematic 
HFNS than did those receiving usual care, and these 
improvements were maintained at both the 9-week and 
26-week follow-up. Although the pre-speciﬁ ed endpoint 
of a between-group diﬀ erence of 2 points on the problem-
rating scale was not met, there was a statistically 
signiﬁ cant improvement in the CBT group, and a large 
proportion of women (78%) who had received CBT 
achieved a reduction of 2 points compared with the usual 
care group (33%) at 26 weeks. However, we recorded no 
signiﬁ cant diﬀ erence in the frequency of HFNS between 
the two groups at either 9 weeks or 26 weeks. Similarly, 
we recorded no signiﬁ cant diﬀ erences between groups in 
24 h rate of HFNS after the treatment phase, either 
physiologically (SSC) deﬁ ned or participant recorded 
(event monitor). Nevertheless, the eﬀ ects of CBT on 
HFNS problem rating were substantial and robust. Most 
women participating in group CBT reported reductions 
in problem rating that are regarded as clinically 
important, and there were sustained signiﬁ cant dif-
ferences in problem rating between CBT and usual care. 
These diﬀ erences were not unduly aﬀ ected by outliers or 
other inﬂ uential points (ie, the average group changes 
were signiﬁ cant), and the sample contained more precise 
standard deviations than we expected.
Additionally, group CBT provided sustained beneﬁ ts to 
depressed mood and sleep and some improvements in 
dimensions of quality of life. At baseline, on average, 
participants had higher scores for sleep problems, 
somatic symptoms, and memory and concentration 
(WHQ) compared with norms for healthy women (table 
3 and data not shown).27 According the the SF-36 scale, 
they had lower scores (lower quality of life) than did 
healthy women, especially for physical role functioning, 
general health, vitality, and bodily pain. The signiﬁ cant 
improve ments in mood and sleep, as well as memory 
and concentration, after CBT are clinically important 
because diﬃ  culties with mood sleep and cognitive 
functions are commonly reported by patients with breast 
cancer, particularly by those with HFNS.30 Moreover, the 
improve ment in social functioning after CBT is relevant 
because women report ﬁ nding hot ﬂ ushes especially 
diﬃ  cult to deal with at work and in other social 
situations.18 Although randomised controlled trials of 
non-hormonal drugs for HFNS have shown moderate 
reductions in HFNS frequency, they have recorded little 
evidence of improved quality of life.9 Similarly, some 
studies show only weak relations between frequency of 
HFNS and quality of life.21,22
The results of our study are very similar to the 
preliminary ﬁ ndings of a parallel trial of CBT for HFNS 
in a sample of healthy women (MENOS2).31 This 
consistent pattern of results suggests that the CBT might 
work by aﬀ ecting symptom perception and cognitive 
appraisal of HFNS and possibly mood, rather than 
physiological mechanisms of HFNS, such as temperature 
regulation or the thermoneutral zone in the hypo-
thalamus.19 Further analyses of moderators and mediators 
of HFNS are planned to clarify this issue through 
identiﬁ cation of the underlying causal pathways to 
improvement on the hot ﬂ ush problem rating scale.20 For 
example, changes in sleep after treatment might partly 
mediate the improvements in mood and quality of life. 
We postulate that hot-ﬂ ush beliefs and behaviours, as 
well as mood and sleep, will act as potential mediators. 
For the moderator analysis, baseline clinical and demo-
graphical characteristics, such as anxiety and depression, 
will be considered alongside factors such as drug use and 
health behaviours. Further studies should examine 
particular components of the intervention to test these 
analyses experimentally.
We postulated that CBT would reduce HFNS frequency 
to a greater extent than would usual care, especially 
because paced breathing has been shown to reduce 
HFNS frequency measured both physiologically and sub-
jectively.32 Women receiving CBT reported practising 
paced breathing daily. Paced breathing, once learnt, is 
practised for 2–5 min throughout the day and at the onset 
of a hot ﬂ ush, so an average of 29 times per week is a 
realistic rate at which to practise. However, participants 
Panel 2: Research in context
Systematic review
We searched OvidSP using a combination of the terms cognitive “behavio*”, “hot ﬂ ush*”, 
“hot ﬂ ash*”, “menopaus*”, and “breast cancer”. We found three relevant studies. One study 
was the MENOS1 single-group pilot trial,18 in which weekly 1·5 h sessions of cognitive 
behavioural therapy (CBT) for 6 weeks resulted in an average 49% reduction in problem 
rating and 38% reduction in hot ﬂ ushes and night sweats (HFNS) frequency, maintained at 
3 months’ follow-up. A larger randomised controlled trial of CBT and exercise,33 which used 
the group protocol manual developed for MENOS 1,18 reported preliminary ﬁ ndings in 
which frequency and problem-rating reduced compared with usual care, although detailed 
ﬁ ndings are not available. In another single-group trial,34 an instructional DVD of paced 
breathing and distraction used over the course of 1 week resulted in small reductions in 
bothersomeness and interference of HFNS and no change in physiologically measured hot 
ﬂ ush frequency. CBT shows some promise but adequately powered randomised controlled 
trials are needed.
Interpretation
Our ﬁ ndings show that group CBT can reduce the eﬀ ect of hot ﬂ ushes and night sweats for 
women who have had breast cancer treatment. These reductions were sustained and 
associated with improvements in mood, sleep, and quality of life. Group CBT seems to be a 
safe, acceptable, and eﬀ ective treatment option which can be incorporated into breast 
cancer survivorship programmes and delivered by trained breast cancer nurses. 
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in both groups reported improvements in HFNS 
frequency. Women in the usual care group did receive 
psycho education, advice (which included paced 
breathing), and nursing support, which could have led to 
reductions in the usual care group, although we did not 
record paced breathing or other techniques done by these 
women. CBT treatment eﬀ ects could have been 
attributable to the placebo eﬀ ect of additional attention in 
the group CBT. However, we controlled for usual care 
and assessment eﬀ ects and we should gain some insight 
into the placebo eﬀ ects of usual care through the planned 
mediator and moderator analysis.20 Further research 
could compare diﬀ erent types of control conditions with 
diﬀ ering levels of information, advice, and support. The 
group CBT programme should be generalisable to other 
breast cancer settings because it is delivered in a hospital 
setting, is done by use of easily transferable guidelines 
(the treatment manual), and adherence to the guidelines 
was high. Drop-out rates were low, and the preliminary 
results of qualitative interviews done at the end of the 
trial suggest that the CBT was highly acceptable. The cost 
of delivering the treatment needs to be assessed, with a 
need for comparison with non-hormonal drugs. The 
most cost-eﬀ ective method of delivering the group CBT 
would probably be to include it as part of survivorship 
support programme, delivered by trained and supervised 
breast-care nurses.
To date, the best available treatments have been non-
hormonal drugs including SSRI and SNRIs, clonidine, and 
gabapentin.9 These treatments have produced moderate 
reductions in HFNS frequency (averaging 37% across 
trials9), but have had little eﬀ ect on quality-of-life measures. 
By contrast our ﬁ ndings suggest that both CBT and usual 
care resulted in a 38% reduction in frequency, and 
compared with the usual care group, those who received 
CBT showed statistically signiﬁ cant and lasting reductions 
in problem rating and improvements in quality of life. CBT 
could, therefore, be an important alternative or additional 
treatment option for patients with breast cancer (panel 2).
Limitations of this study include the frequency meas-
ures, which had high variability. The main subjective 
measure (hot ﬂ ush rating scale) is retrospective—daily 
diary measures might be more reliable. However, ﬁ ndings 
from another study show evidence of the validity of this 
scale compared with daily diary measures.24 Estimation of 
the frequency of night sweats with the hot ﬂ ush rating 
scale can be more diﬃ  cult because women do not report 
night sweats that they sleep through, but this limitation is 
common to all self-report measures. The physiological 
measure was used for 24 h at baseline and at 9 weeks after 
randomisation; in view of the variability of this measure, 
future studies might include a longer time of SSC 
monitoring and also include this measure at follow-up 
assessments. Addition ally, we did not control for all 
potential confounding factors that could have an eﬀ ect on 
menopausal symptoms, such as the use of drugs to manage 
HFNS and the use of adjuvant hormone therapy. Health 
behaviours might also have aﬀ ected HFNS and other 
secondary outcomes, but were not controlled for in the 
analyses (eg, caﬀ eine intake). Finally, we do not know 
whether HFNS were caused by breast cancer treatments or 
whether women were naturally menopausal when they 
had breast cancer. However, treatment options are still 
restricted for these women, so a need still exists for non-
hormonal interventions.
Our ﬁ ndings suggest that this cognitive behavioural 
treatment, designed to be delivered by trained health 
professionals such as breast-care nurses, has the potential 
to improve long-term health outcomes for patients with 
breast cancer, and could be incorporated into breast 
cancer survivorship programmes.
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